S‐mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.

16Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A mephenytoin test was carried out in 106 unrelated healthy Turkish volunteers. Racemic mephenytoin was coadministered with either debrisoquine or sparteine. The S/R mephenytoin ratio ranged from < 0.1 to 0.73 in 105 subjects, accordingly phenotyped as extensive metabolisers. One subject had an S/R mephenytoin ratio of 1.02, showing that he was a poor metaboliser of mephenytoin (0.94%, confidence interval 0.25% and 13.65%). In 48 subjects, the metabolic ratios of debrisoquine and sparteine were correlated significantly (rs = 0.61, P < 0.001). 1994 The British Pharmacological Society

Cite

CITATION STYLE

APA

Basci, N., Brosen, K., Bozkurt, A., Isimer, A., Sayal, A., & Kayaalp, S. (1994). S‐mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population. British Journal of Clinical Pharmacology, 38(5), 463–465. https://doi.org/10.1111/j.1365-2125.1994.tb04383.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free